For the year ending 2025-12-31, JANX made $10,000K in revenue. -$111,472K in net income. Net profit margin of -1114.72%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Collaboration revenue | 10,000 | 10,588 | ||
| Research and development | 125,896 | 68,388 | ||
| General and administrative | 41,771 | 41,047 | ||
| Total operating expenses | 167,667 | 109,435 | ||
| Loss from operations | -157,667 | -98,847 | ||
| Interest income | 44,042 | 29,853 | ||
| Total other income | 44,042 | 29,853 | ||
| Net loss | -113,625 | -68,994 | ||
| Unrealized gain on available-for-sale securities, net | 2,153 | 1,498 | ||
| Comprehensive loss | -111,472 | -67,496 | ||
| Basic EPS | -1.83 | -1.28 | ||
| Diluted EPS | -1.83 | -1.28 | ||
| Basic Average Shares | 61,966,999 | 53,751,480 | ||
| Diluted Average Shares | 61,966,999 | 53,751,480 | ||
Janux Therapeutics, Inc. (JANX)
Janux Therapeutics, Inc. (JANX)